Livzon pharmaceutical reports mixed Q3 results amid overall nine-month growth

Livzon Pharmaceutical Group Inc. reported operating income of 9.12 bn yuan for the first nine months of 2025, a slight increase of 0.38% compared to the previous year. Net profit attributable to shareholders rose by 4.86% to 1.75 bn yuan, while net cash flow from operating activities saw a substantial 9.42% increase, reaching 2.53 bn yuan. Basic and diluted earnings per share were 1.96 yuan, up 8.29%.

However, the third quarter (July-September 2025) presented a mixed picture, with operating income increasing by 1.60% to 2.84 bn yuan, but net profit attributable to shareholders declining by 5.73% to 473.01 m yuan. The weighted average return on net assets also decreased by 0.15 percentage points to 3.41% for the third quarter.

Total assets grew by 0.34% to 24.54 bn yuan, and owners' equity attributable to shareholders rose by 0.73% to 13.96 bn yuan by the end of the reporting period. The company also repurchased 15,376,845 A Shares, totaling 570.23 m yuan.